Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-ONCO-01
- Development stage
- Preclinical
- Lead developer
- Kantify
- Modality
- Small Molecules
01
Overview
KAN-ONCO-01 is a preclinical-stage small molecule drug candidate being developed by Kantify in collaboration with Johns Hopkins University for the treatment of metastatic prostate cancer. Discovered using Kantify's proprietary Sapian™ AI platform, the compound is designed to target a specific tumor-associated antigen. The program leverages AI-driven drug discovery to identify small molecules capable of modulating challenging oncology targets. KAN-ONCO-01 is currently undergoing preclinical validation, including hit discovery and lead optimization, to evaluate its efficacy and safety profile for advanced prostate cancer therapy.
Beyond the preview
Go deeper on KAN-ONCO-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-ONCO-01.